Radiotherapy with genomic-adjusted radiation dose - Authors' reply

Jacob G Scott¹, Geoffrey Sedor², Jessica A Scarborough¹, Michael W Kattan³, Javier F Torres-Roca⁴

Affiliations

¹ School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Translational Hematology and Oncology Research and Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
² School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
³ Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
⁴ Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Electronic address: javier.torresroca@moffitt.org.

PMID: 34735812
DOI: 10.1016/S1470-2045(21)00601-X

Comment

Radiotherapy with genomic-adjusted radiation dose - Authors' reply

Jacob G Scott et al. Lancet Oncol. 2021 Nov.

. 2021 Nov;22(11):e470-e471.

doi: 10.1016/S1470-2045(21)00601-X.

Authors

Jacob G Scott¹, Geoffrey Sedor², Jessica A Scarborough¹, Michael W Kattan³, Javier F Torres-Roca⁴

Affiliations

¹ School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Translational Hematology and Oncology Research and Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
² School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
³ Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
⁴ Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Electronic address: javier.torresroca@moffitt.org.

PMID: 34735812
DOI: 10.1016/S1470-2045(21)00601-X

No abstract available

PubMed Disclaimer

Conflict of interest statement

JGS and JFT-R hold intellectual property on RSI, GARD, and prescription dose base on RSI (known as RxRSI), in addition to equity in Cvergenx, a company that seeks to commercialise these methods. Patents held by Moffitt Cancer Center are as follows: RSI (awarded) patent number 7 879 545; 8 655 598; 8 660 801, and 9 846 762; GARD (awarded) patent number 10 697 023; and Cvergenx (RxRSI [pending] application number 16/658 961). JFT-R is a cofounder and board member of Cvergenx. All other authors declare no competing interests.

Comment on

A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. Scott JG, et al. Lancet Oncol. 2017 Feb;18(2):202-211. doi: 10.1016/S1470-2045(16)30648-9. Epub 2016 Dec 18. Lancet Oncol. 2017. PMID: 27993569 Free PMC article.
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.
Scott JG, Sedor G, Ellsworth P, Scarborough JA, Ahmed KA, Oliver DE, Eschrich SA, Kattan MW, Torres-Roca JF. Scott JG, et al. Lancet Oncol. 2021 Sep;22(9):1221-1229. doi: 10.1016/S1470-2045(21)00347-8. Epub 2021 Aug 4. Lancet Oncol. 2021. PMID: 34363761
Radiotherapy with genomic-adjusted radiation dose.
Kashihara T, Kashihara K. Kashihara T, et al. Lancet Oncol. 2021 Nov;22(11):e468. doi: 10.1016/S1470-2045(21)00541-6. Lancet Oncol. 2021. PMID: 34735810 No abstract available.
Radiotherapy with genomic-adjusted radiation dose.
Musunuru HB, Keller A, Beriwal S. Musunuru HB, et al. Lancet Oncol. 2021 Nov;22(11):e469. doi: 10.1016/S1470-2045(21)00583-0. Lancet Oncol. 2021. PMID: 34735811 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Radiotherapy with genomic-adjusted radiation dose - Authors' reply

Affiliations

Radiotherapy with genomic-adjusted radiation dose - Authors' reply

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources